{"id":"W2003693083","doi":"10.1016/j.rmed.2015.02.012","title":"A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease","year":2015,"lang":"en","type":"article","venue":"Respiratory Medicine","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada); University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; COPD; Placebo; Bronchodilator; Anesthesia; Dose-ranging study; Pulmonary function testing; Clinical endpoint; Area under the curve; Pharmacokinetics; Internal medicine; Randomized controlled trial; Asthma; Double blind","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001074941,0.0007365728,0.002079692,0.0007075997,0.0002147601,0.00001852997,0.0002575354,0.0001575586,0.00009400411],"category_scores_gemma":[0.000755631,0.0004747057,0.0002782467,0.0006427081,0.0008121935,0.0003282941,0.00009006412,0.0004002518,0.000003264679],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002696526,"about_ca_system_score_gemma":0.00341571,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001623309,"about_ca_topic_score_gemma":0.00007437527,"domain_scores_codex":[0.9950002,0.0002744805,0.001188567,0.001044429,0.001486813,0.001005495],"domain_scores_gemma":[0.9959154,0.0005937528,0.0006730873,0.0008905095,0.0007206211,0.001206595],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.939076,0.005512432,0.02306273,0.0006726094,0.0006943884,0.0005372425,0.0006194592,0.0001987501,0.0006278876,0.0000142289,0.00004876139,0.0289355],"study_design_scores_gemma":[0.9370646,0.03460102,0.02053204,0.00129781,0.001302615,0.00001665451,0.0005712218,0.002466771,0.0001749065,0.00001508259,0.001515315,0.0004419803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804288,0.002311716,0.0004479343,0.0004241609,0.0002518233,0.01513836,0.000196436,0.00007393175,0.0007269067],"genre_scores_gemma":[0.9952608,0.00001869256,0.0001986214,0.0001121927,0.001019913,0.002614326,0.0002655759,0.0001367595,0.000373085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02908859,"threshold_uncertainty_score":0.9997705,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03866285701502193,"score_gpt":0.3217502101785243,"score_spread":0.2830873531635024,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}